Gill Capital Partners’s Moderna MRNA Stock Holding History

Gill Capital Partners’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$980	Hold	14	–	–	﹤0.01%	618
2026 Q1	$711	Buy	+14	New	+$653	﹤0.01%	616

Other funds holding MRNA

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.68B AUM 19.9% 1-Year Est. Return

Gill Capital Partners's MRNA Position: Q2 2026 in Review

Gill Capital Partners held its Moderna (MRNA) position steady in Q2 2026 at 14 shares worth $980. The position accounts for ﹤0.01% of the portfolio, ranked #618.

Gill Capital Partners first reported a position in MRNA in Q1 2026 and has held it in 2 quarters since. 782 funds tracked by Wall St. Rank hold MRNA as of Q2 2026.

Gill Capital Partners held 14 shares of Moderna worth $980 as of Q2 2026.
Gill Capital Partners left its Moderna share count unchanged in Q2 2026.
Moderna made up ﹤0.01% of Gill Capital Partners's portfolio in Q2 2026, its #618 holding.
Gill Capital Partners first reported a position in Moderna in Q1 2026 and has held it in 2 quarters since.
782 funds tracked by Wall St. Rank held Moderna as of Q2 2026.

Based on Gill Capital Partners's 13F filing for Q2 2026, filed 20 Aug 2026.